Clearside Biomedical Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Clearside Biomedical has been growing earnings at an average annual rate of 3.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 12.2% per year.
Información clave
3.5%
Tasa de crecimiento de los beneficios
22.5%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 6.0% |
Tasa de crecimiento de los ingresos | 12.2% |
Rentabilidad financiera | n/a |
Margen neto | -444.7% |
Próxima actualización de resultados | 12 Nov 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Desglose de ingresos y gastos
Cómo gana y gasta dinero Clearside Biomedical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 24 | 8 | -33 | 11 | 22 |
31 Mar 24 | 8 | -35 | 12 | 22 |
31 Dec 23 | 8 | -32 | 12 | 21 |
30 Sep 23 | 2 | -37 | 12 | 20 |
30 Jun 23 | 2 | -36 | 12 | 19 |
31 Mar 23 | 1 | -35 | 11 | 20 |
31 Dec 22 | 1 | -33 | 12 | 20 |
30 Sep 22 | 27 | -5 | 12 | 18 |
30 Jun 22 | 29 | -2 | 12 | 19 |
31 Mar 22 | 30 | 0 | 12 | 18 |
31 Dec 21 | 30 | 0 | 12 | 19 |
30 Sep 21 | 4 | -25 | 11 | 19 |
30 Jun 21 | 4 | -23 | 11 | 18 |
31 Mar 21 | 4 | -23 | 11 | 17 |
31 Dec 20 | 8 | -18 | 11 | 15 |
30 Sep 20 | 10 | -14 | 12 | 12 |
30 Jun 20 | 7 | -18 | 13 | 9 |
31 Mar 20 | 6 | -18 | 16 | 9 |
31 Dec 19 | 2 | -31 | 17 | 16 |
30 Sep 19 | 0 | -49 | 17 | 32 |
30 Jun 19 | 0 | -67 | 17 | 52 |
31 Mar 19 | 0 | -82 | 16 | 66 |
31 Dec 18 | 0 | -83 | 15 | 68 |
30 Sep 18 | 0 | -78 | 13 | 65 |
30 Jun 18 | 0 | -72 | 11 | 61 |
31 Mar 18 | 0 | -65 | 10 | 55 |
31 Dec 17 | 0 | -59 | 10 | 49 |
30 Sep 17 | 0 | -52 | 10 | 42 |
30 Jun 17 | 0 | -39 | 9 | 30 |
31 Mar 17 | 0 | -31 | 8 | 22 |
31 Dec 16 | 1 | -26 | 6 | 19 |
30 Sep 16 | 1 | -21 | 5 | 16 |
30 Jun 16 | 1 | -19 | 5 | 15 |
31 Mar 16 | 1 | -19 | 7 | 13 |
31 Dec 15 | 0 | -18 | 7 | 11 |
30 Sep 15 | 0 | -15 | 6 | 9 |
30 Jun 15 | 0 | -15 | 6 | 9 |
31 Mar 15 | 0 | -12 | 4 | 8 |
31 Dec 14 | 0 | -10 | 3 | 7 |
30 Sep 14 | 0 | -9 | 3 | 6 |
30 Jun 14 | 0 | -8 | 3 | 5 |
31 Mar 14 | 0 | -8 | 2 | 5 |
Ingresos de calidad: CLSD is currently unprofitable.
Margen de beneficios creciente: CLSD is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CLSD is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.
Acelerando crecimiento: Unable to compare CLSD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: CLSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rentabilidad financiera
Alta ROE: CLSD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.